Empagliflozin and Linagliptin Tablets – Dual Action Diabetes Control with EMPATECH LINA 25/5

Mechanism of Action

• Empagliflozin is an SGLT2 inhibitor that works by blocking glucose reabsorption in the kidneys, leading to increased urinary glucose excretion and lowering blood sugar levels.

• Linagliptin, a DPP-4 inhibitor, increases the levels of incretin hormones, enhancing insulin release and decreasing glucagon secretion in a glucose-dependent manner.

Together in empagliflozin and linagliptin tablets, this combination provides comprehensive glycemic control with complementary actions—insulin-independent and insulin-dependent pathways.

Uses and Indications

EMPATECH LINA 25/5 is indicated for:

• Management of Type 2 Diabetes Mellitus in adults

• Patients inadequately controlled on either empagliflozin tablets 25 mg or linagliptin tablets alone

• Reduction of cardiovascular risk in diabetic patients with established heart disease
  As part of a treatment plan including diet and exercise

This fixed dose combination of empagliflozin and linagliptin tablets ensures therapeutic synergy and improved patient compliance.

Efficacy and Clinical Evidence

• Clinical studies have shown that the fixed dose combination of empagliflozin and linagliptin tablets offers superior HbA1c reduction compared to monotherapy.

• A 24-week randomized controlled trial demonstrated significant improvements in fasting plasma glucose, postprandial glucose, and body weight.

• Empagliflozin has been proven to reduce cardiovascular mortality and hospitalization for heart failure, while linagliptin adds robust glycemic control with a low risk of hypoglycemia.
  
  

Side Effects and Safety Profile

Common side effects:

• Urinary tract infections (due to empagliflozin)

• Nasopharyngitis

• Headache

• Increased urination

• Mild gastrointestinal discomfort

Serious but rare side effects:

• Ketoacidosis (rare with SGLT2 inhibitors)

• Hypoglycemia (when combined with sulfonylureas or insulin)

• Pancreatitis (rare with linagliptin)

• Dehydration and hypotension

Overall, empagliflozin and linagliptin tablets have a favorable safety profile when used appropriately under medical supervision.

Contraindications and Precautions

Contraindications:

• Type 1 diabetes or diabetic ketoacidosis

• Severe renal impairment or end-stage renal disease

• Known hypersensitivity to empagliflozin tablets 25 mg or linagliptin tablets

Precautions:

• Monitor kidney function regularly

• Use with caution in elderly patients or those on diuretics

• Ensure adequate hydration to avoid volume depletion

Drug Interactions

• Diuretics: May enhance risk of hypotension or dehydration

• Insulin or sulfonylureas: Increased risk of hypoglycemia

• Rifampin: May reduce plasma concentrations of linagliptin

• Avoid co-administration with other DPP-4 or SGLT2 inhibitors

Warnings and Regulatory Status

• Approved by global regulatory agencies including USFDA and EMA

• Regular blood sugar and kidney function monitoring recommended

• Not recommended in patients with Type 1 diabetes or history of ketoacidosis

• Use during pregnancy only if clearly needed and prescribed by a physician

Patient Advice and Tips

• Take EMPATECH LINA 25/5 once daily, preferably in the morning

• Stay well hydrated throughout the day

• Follow a balanced diet and exercise routine

• Monitor blood glucose regularly

• Inform your doctor if you experience signs of urinary tract infections, extreme thirst, or abdominal pain

Availability

EMPATECH LINA 25/5 is widely available across pharmacies in India through Steris Healthcare’s trusted distributor network. It is also accessible through leading online platforms and hospital supply chains. Always ensure you’re purchasing from a verified medical source.

 Frequently Asked Questions

1. What is EMPATECH LINA 25/5 used for?
It is used to treat type 2 diabetes mellitus, especially in patients inadequately controlled with single-drug therapy.

2. Can EMPATECH LINA cause low blood sugar?
It typically doesn’t cause hypoglycemia unless combined with insulin or sulfonylureas.

3. How long before I see results?
Improvement in blood sugar can be seen within a few days, with full effect over 2–4 weeks.

4. Is it safe for kidney patients?
It should be used with caution in patients with reduced kidney function and is not recommended for those with severe renal impairment.

5. Can I take this with other diabetes medicines?
Yes, but only under a doctor’s supervision to avoid interactions or low blood sugar.

Why Choose Steris Healthcare Pvt Ltd?

• WHO-GMP Certified Manufacturing – Ensures international quality

• Innovative Fixed-Dose Combinations like EMPATECH LINA for improved compliance

• Affordable pricing without compromising safety and efficacy

• Strong distribution network ensures consistent availability

• Ethical practices and customer-centric policies make Steris a trusted pharmaceutical partner

Conclusion

EMPATECH LINA 25/5, a fixed-dose combination of empagliflozin and linagliptin tablets, offers a modern, effective, and patient-friendly solution for adults with type 2 diabetes. By targeting two different pathways, it improves glycemic control, reduces cardiovascular risk, and minimizes pill burden. With a proven safety profile, strong clinical evidence, and accessibility across India, this formulation by Steris Healthcare Pvt Ltd represents the next step in diabetes care.